1-10 of 10
Alejandra Raimondi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Yeying Huang, R. Taylor Durall, Nhi M. Luong, Hans J. Hertzler, Julianna Huang, Prafulla C. Gokhale, Brittaney A. Leeper, Nicole S. Persky, David E. Root, Praju V. Anekal, Paula D.L.M. Montero Llopis, Clement N. David, Jeffery L. Kutok, Alejandra Raimondi, Karan Saluja, Jia Luo, Cynthia A. Zahnow, Biniam Adane, Kimberly Stegmaier, Catherine E. Hawkins, Christopher Ponne, Quan Le, Geoffrey I. Shapiro, Madeleine E. Lemieux, Kyle P. Eagen, Christopher A. French
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3956–3973.
https://doi.org/10.1158/0008-5472.CAN-23-1475
Published: 01 December 2023
View article titled, EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes
Open the PDF for EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes in another window
Includes: Supplementary data
Journal Articles

Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma

Jeffrey A. Keats, Arleide Lee, Jeremy C. Cunniff, Weiqing Chen, Revonda Mehovic, Vania Estanek, Crag Markwood, Cuyue Tang, Daniel T. Dransfield, Veronica Gibaja, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1161.
https://doi.org/10.1158/1538-7445.AM2021-1161
Published: 01 July 2021
View article titled, Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma
Journal Articles

Abstract 2924: Aberrant SWI/SNF complexes lacking SMARCA2 or SMARCA4 differentially affect cell state and response to a novel SMARCA2/4 inhibitor

Lindsey W. Eichinger, Chloe Pantano, Vinny Motwani, Dorothy Brach, Selene Howe, Alejandra Raimondi, Daniel T. Dransfield, Kenneth W. Duncan, Kim Stickland, Cuyue Tang, Neil A. Farrow, John Lampe, Suzanne L. Jacques, Allison E. Drew
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2924.
https://doi.org/10.1158/1538-7445.AM2020-2924
Published: 15 August 2020
View article titled, Abstract 2924: Aberrant SWI/SNF complexes lacking SMARCA2 or SMARCA4 differentially affect cell state and response to a novel SMARCA2/4 inhibitor
Journal Articles

Abstract 1768: Identification of a potent, orally-available SMARCA2/4 inhibitor with in vitro and in vivo activity in preclinical models of SMARCA4-mutant NSCLC

Allison E. Drew, Suzanne L. Jacques, Lindsey W. Eichinger, Chloe Pantano, Vinny Motwani, Cuyue Tang, Cuyue Tang, Neil Farrow, Dorothy Brach, Selene Howe, Alejandra Raimondi, Daniel T. Dransfield, Kenneth W. Duncan, Kim Stickland, Liyue Huang, John Lampe
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1768.
https://doi.org/10.1158/1538-7445.AM2020-1768
Published: 15 August 2020
View article titled, Abstract 1768: Identification of a potent, orally-available SMARCA2/4 inhibitor with in vitro and in vivo activity in preclinical models of SMARCA4-mutant NSCLC
Journal Articles

Abstract 807: Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models

Allison E. Drew, Vinny Motwani, Lindsey Eichinger, Jesse Smith, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 807.
https://doi.org/10.1158/1538-7445.AM2018-807
Published: 01 July 2018
View article titled, Abstract 807: Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models
Journal Articles

Abstract 808: Opportunity for therapeutic expansion in mantle cell lymphoma: Tazemetostat combination synergy status in preclinical MCL models

Tami L. Hood, Kat Cosmopoulos, Allison Drew, Kelli Armstrong, Jennifer Johnson, Smith Jesse, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 808.
https://doi.org/10.1158/1538-7445.AM2018-808
Published: 01 July 2018
View article titled, Abstract 808: Opportunity for therapeutic expansion in mantle cell lymphoma: Tazemetostat combination synergy status in preclinical MCL models
Journal Articles

Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models

Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R. Grassian, Igor Feldman, Maria Roche, Peter Ho, Dorothy Brach, Alejandra Raimondi, Robert A. Copeland, Richard Chesworth, Jesse J. Smith, Scott A. Ribich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3345.
https://doi.org/10.1158/1538-7445.AM2017-3345
Published: 01 July 2017
View article titled, Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: <em>In vitro</em> and <em>in vivo</em> preclinical models
Journal Articles

Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models

Allison E. Drew, Vinny Motwani, John E. Campbell, Cuyue Tang, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, Alejandra Raimondi, Scott Ribich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5060.
https://doi.org/10.1158/1538-7445.AM2017-5060
Published: 01 July 2017
View article titled, Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Journal Articles

Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT

Christine R. Klaus, Jeffrey A. Keats, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, Scott Ribich, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1944.
https://doi.org/10.1158/1538-7445.AM2017-1944
Published: 01 July 2017
View article titled, Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT
Journal Articles

Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia

Christine R. Klaus, Scott R. Daigle, Vivek Chopra, Jeffrey A. Keats, Carly T. Campbell, Dorothy Iwanowicz, Edward J. Olhava, Margaret P. Scott, Roy M. Pollock, Robert A. Copeland, Jesse J. Smith, Jorge DiMartino, Stephen J. Blakemore, Alejandra Raimondi
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5383.
https://doi.org/10.1158/1538-7445.AM2015-5383
Published: 01 August 2015
View article titled, Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia